StockpollyBeta
Get App
Popularity #4,076
MNOV · NASDAQ · Biotechnology

MediciNova (MNOV)

Develops in-licensed small molecules across neurodegenerative, metabolic, and fibrotic diseases.

$2.85
After hours−0.05 (−1.73%)
At close$2.90(−12.12%)

  1. MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

    Zacks Investment Research

  2. MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

    GlobeNewsWire

  3. MediciNova CEO Provides Shareholder Update

    GlobeNewsWire

  4. MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

    GlobeNewsWire

  5. MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

    GlobeNewsWire

  6. MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average – Here’s What Happened

    Defense World

  7. MediciNova to Participate at the 38th Annual ROTH Conference

    GlobeNewsWire

  8. MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

    Defense World

  9. MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

    GlobeNewsWire

  10. MediciNova, Inc. (NASDAQ:MNOV) Receives $7.00 Average Target Price from Analysts

    Defense World

  11. 2026 New Year's Greetings from the CEO

    GlobeNewsWire

  12. MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

    GlobeNewsWire

  13. MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

    GlobeNewsWire

  14. MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

    GlobeNewsWire

  15. MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

    GlobeNewsWire

  16. MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

    GlobeNewsWire

  17. MediciNova to Present at the LD Micro Main Event XIX Investor Conference

    GlobeNewsWire

  18. MediciNova Provides Shareholder Update on Key Developments

    GlobeNewsWire

  19. MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    GlobeNewsWire

  20. MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

    GlobeNewsWire